122 related articles for article (PubMed ID: 16897976)
1. [Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen].
Komatsu Y; Yuki S; Miyagishima T; Asaka M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():75-8. PubMed ID: 16897976
[TBL] [Abstract][Full Text] [Related]
2. [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
Komatsu Y; Yuki S; Tateyama M; Kudo M; Asaka M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():131-4. PubMed ID: 16897988
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
[TBL] [Abstract][Full Text] [Related]
4. Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
Komatsu Y; Yuki S; Fuse N; Kato T; Miyagishima T; Kudo M; Kunieda Y; Tateyama M; Wakahama O; Meguro T; Sakata Y; Asaka M
Adv Ther; 2010 Jul; 27(7):483-92. PubMed ID: 20559897
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.
Inokuchi M; Yamashita T; Yamada H; Kojima K; Ichikawa W; Nihei Z; Kawano T; Sugihara K
Br J Cancer; 2006 Apr; 94(8):1130-5. PubMed ID: 16570038
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M
Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).
Takiuchi H; Narahara H; Tsujinaka T; Gotoh M; Kawabe S; Katsu K; Iishi H; Tatsuta M; Fujitani K; Furukawa H; Taguchi T;
Jpn J Clin Oncol; 2005 Sep; 35(9):520-5. PubMed ID: 16141295
[TBL] [Abstract][Full Text] [Related]
8. [S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer].
Hyodo I
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():64-7. PubMed ID: 16897974
[TBL] [Abstract][Full Text] [Related]
9. [S-1 for gastric cancer-S-1 monotherapy and its progress].
Shitara K; Sakata Y; Kudou T; Munakata M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():43-51. PubMed ID: 16897971
[TBL] [Abstract][Full Text] [Related]
10. A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Kamijo A
Oncology; 2015; 88(6):353-9. PubMed ID: 25592116
[TBL] [Abstract][Full Text] [Related]
11. A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
Hata T; Fukunaga M; Murata K; Uemura Y; Fukuzaki T; Ota H; Ohue M; Ohnishi T; Tanaka N; Takemasa I; Mizushima T; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1657-63. PubMed ID: 23543294
[TBL] [Abstract][Full Text] [Related]
12. [Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer].
Akasaka O; Iwase S; Miwa H; Ando T; Morita S; Koh R; Kasama M; Matsueda R; Anan H
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1833-7. PubMed ID: 19920384
[TBL] [Abstract][Full Text] [Related]
13. Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.
Chon HJ; Rha SY; Park HS; Shin SJ; Kim HS; Roh JK; Noh SH; Chung HC; Jeung HC
Cancer Chemother Pharmacol; 2011 Oct; 68(4):991-9. PubMed ID: 21327684
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.
Yamada Y; Yasui H; Goto A; Arai T; Ura T; Hamaguchi T; Muro K; Shimada Y; Shirao K
Int J Clin Oncol; 2003 Dec; 8(6):374-80. PubMed ID: 14663640
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
[TBL] [Abstract][Full Text] [Related]
16. A phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer.
Iwase H; Shimada M; Tsuzuki T; Horiuchi Y; Kumada S; Haruta J; Yamaguchi T; Sugihara M; Ina K; Kusugami K; Goto S
Anticancer Res; 2005; 25(2B):1297-301. PubMed ID: 15865081
[TBL] [Abstract][Full Text] [Related]
17. [A case of unresectable advanced gastric cancer successfully treated with continuous S-1 + CPT-11 chemotherapy accompanied by dose reduction against grade 4 hematological adverse event].
Miyazaki Y; Imamura H; Kishimoto T; Furukawa H; Ota K; Tatsuta M
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2060-2. PubMed ID: 19106523
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Tsunoda A; Yasuda N; Nakao K; Narita K; Watanabe M; Matsui N; Kusano M
Oncology; 2009; 77(3-4):192-6. PubMed ID: 19729976
[TBL] [Abstract][Full Text] [Related]
19. A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
Sato T; Ozawa H; Hatate K; Onosato W; Naito M; Nakamura T; Ihara A; Koizumi W; Hayakawa K; Okayasu I; Yamashita K; Watanabe M
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):677-83. PubMed ID: 21035953
[TBL] [Abstract][Full Text] [Related]
20. A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
Huang D; Ba Y; Xiong J; Xu N; Yan Z; Zhuang Z; Yu Z; Wan H; Zhang Y; Deng T; Zheng R; Guo Z; Hu C; Wang M; Yu Z; Yao Y; Meng J
Eur J Cancer; 2013 Sep; 49(14):2995-3002. PubMed ID: 23810466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
